BACKGROUND: Pelvic exenteration is a potentially curative treatment for locally advanced primary @entity5 . Previous studies have been limited by small sample sizes and heterogeneous data. A consecutive series of @entity1 was studied to identify the clinicopathological determinants of survival. METHODS: All @entity1 undergoing pelvic exenterative surgery for primary @entity5 (1992-2014) at this hospital were analysed. The primary outcome measure was 5-year overall survival. Secondary endpoints included length of hospital stay, complication rate, 30-day mortality and disease recurrence rate. Statistical analysis was performed using Kaplan-Meier and Cox regression analysis. RESULTS: A total of 174 @entity1 with a median age of 65 (range 31-90) years were included. Ninety-six @entity1 underwent posterior pelvic exenteration and 78 had total pelvic exenteration. Median follow-up was 48 (range 1-229) months. Two @entity1 (1  1 per cent) died within 30 days of surgery and 16  1 per cent returned to the operating theatre. The 5-year survival rate following complete resection (R0) was 59  3 per cent. In univariable analysis, adverse survival was associated with advanced age (P = 0  003), @entity3 (P = 0  001), pathological node status (P = 0  001), circumferential resection margin (P = 0  001), local recurrence (P = 0  015) and the need for neoadjuvant therapy (P = 0  039). CONCLUSION: Pelvic exenteration is an aggressive treatment option with a high morbidity rate that provides favourable long-term outcomes in @entity1 with locally advanced primary @entity5 .

Determinants of survival following pelvic exenteration for primary XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['rectal cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity5 :: (MESH:D009369,Disease) :: ['rectal cancer']
